Top Tweets for #commitments

TrumpRx is a shiny distraction. For insured Americans, it mostly does nothing — and it can even make costs worse. It’s a cash-only gimmick that bypasses insurance, doesn’t count toward deductibles or out-of-pocket caps, and helps only a narrow slice of people. Meanwhile, it leaves the real problem untouched: high list prices, rebate games, and PBM opacity. Selective discounts in one channel just give drug companies cover to raise prices elsewhere, which hits insured patients through higher premiums and cost-sharing [1][2][3][4]. Bottom line: no structural reform, no leverage, no relief for most families. Just Trump slapping his name on “healthcare” while real affordability crises — housing, healthcare premiums, groceries — keep getting worse. TrumpRx is branding, not policy [5][6]. Citations [1] STAT News — Feb. 5, 2026 "TrumpRx promises drug savings. Experts say insured patients may see little benefit." https://t.co/qlmFPrNX35 [2] PharmaSource Global — 2026 "TrumpRx launches: Will a direct-to-consumer platform actually lower drug costs?" https://t.co/GudOkRUfq6 [3] Dusetzina, S. et al. — 2023 "Association of rebate structures, list prices, and patient out-of-pocket costs in U.S. drug markets." PubMed Central https://t.co/m5vckMwAXx [4] Sood, N. et al. — 2023 "Manufacturer discounts, list-price inflation, and cost shifting in prescription drugs." PubMed Central https://t.co/aPlIwEVpsF [5] Bipartisan Policy Center — 2026 "What TrumpRx means for pharmacies, insurers, and plan sponsors." https://t.co/cHgu7PRYKQ [6] Leonard Davis Institute of Health Economics, University of Pennsylvania — 2025 "Unpacking the federal drug-price reduction struggle." https://t.co/PduIJ0YxMe